This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

18 Nov 2011

Forecast Says Cancer Vaccines Market to Reach $9.1B by 2018

A recent market study estimates that the global cancer vaccines market is expected to reach $9.1bn by 2018.

According to GlobalData’s new report, Cancer Vaccines – Pipeline Assessment and Market Forecasts to 2018, the global cancer vaccines market was worth $3.5bn in 2010, after increasing at a compound annual growth rate (CAGR) of 63.7% during 2006–2010. From 2010–2018, the market is expected to record a CAGR of 12.7%, to reach $9.1bn by 2018.


The report notes that the prophylactic cancer vaccines market experienced high growth during 2006–2010 due to the launch of Gardasil (human papillomavirus quadrivalent (types 6, 11, 16, and 18) vaccine, recombinant) and Cervarix (human papillomavirus bivalent (types 16 and 18) vaccine, recombinant).


New indications for Gardasil are expected to grow the prophylactic cancer vaccines marke

Related News